{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:45:27Z","timestamp":1790815527588,"version":"4.1.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.semarthrit.2012.03.013","type":"journal-article","created":{"date-parts":[[2012,5,2]],"date-time":"2012-05-02T21:47:30Z","timestamp":1335995250000},"page":"166-178","source":"Crossref","is-referenced-by-count":52,"title":["Challenges Associated with the Management of Gouty Arthritis in Patients with Chronic Kidney Disease: A Systematic Review"],"prefix":"10.1016","volume":"42","author":[{"given":"Rodolfo V.","family":"Curiel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas J.","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2012.03.013_bib1","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1185\/03007995.2010.533647","article-title":"Chronic gout: Epidemiology, disease progression, treatment and disease burden","volume":"26","author":"Brook","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2012.03.013_bib2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1745-7599.2010.00556.x","article-title":"The current state of care in gout: Addressing the need for better understanding of an ancient disease","volume":"22","author":"Zychowicz","year":"2010","journal-title":"J Am Acad Nurse Pract"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","article-title":"Prevalence of contraindications and prescription of pharmacologic therapies for gout","volume":"124","author":"Keenan","year":"2011","journal-title":"Am J Med"},{"issue":"Suppl 10","key":"10.1016\/j.semarthrit.2012.03.013_bib4","first-page":"S365","article-title":"Individuals in the US general population with gout and hyperuricemia have significantly higher comorbidities: The national health and nutrition examination survey (NHANES) 2007-2008 [Abstract 879]","volume":"62","author":"Pandya","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrneph.2010.186","article-title":"Challenges of conducting a trial of uric-acid-lowering therapy in CKD","volume":"7","author":"Badve","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib6","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/MNH.0b013e328330d9d0","article-title":"Uric acid: A novel mediator and marker of risk in chronic kidney disease?","volume":"18","author":"Feig","year":"2009","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib7","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1093\/ndt\/gfq740","article-title":"Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: The Jerusalem Lipid Research Clinic cohort study","volume":"26","author":"Ben-Dov","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib8","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000324847","article-title":"Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease","volume":"33","author":"Kanbay","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/j.ajkd.2010.01.019","article-title":"Association of uric acid with change in kidney function in healthy normotensive individuals","volume":"56","author":"Bellomo","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/MAJ.0b013e3181db6e16","article-title":"Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population","volume":"339","author":"Chang","year":"2010","journal-title":"Am J Med Sci"},{"issue":"Suppl 6","key":"10.1016\/j.semarthrit.2012.03.013_bib11","first-page":"S65","article-title":"High levels of uric acid correlate with decline of glomerular filtration rate in chronic kidney disease","volume":"93","author":"Satirapoj","year":"2010","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/archinternmed.2008.605","article-title":"Risk factors for end-stage renal disease: 25-Year follow-up","volume":"169","author":"Hsu","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib13","first-page":"66","article-title":"A preliminary investigation of the association between serum uric acid and impaired renal function","volume":"32","author":"Chen","year":"2009","journal-title":"Chang Gung Med J"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib14","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1093\/ndt\/gfp272","article-title":"Uric acid is associated with the rate of residual renal function decline in peritoneal dialysis patients","volume":"24","author":"Park","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1751-7176.2009.00101.x","article-title":"Uric acid as a marker for renal dysfunction in hypertensive women on diuretic and nondiuretic therapy","volume":"11","author":"Borges","year":"2009","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib16","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1093\/ndt\/gfn767","article-title":"Community-based study on CKD subjects and the associated risk factors","volume":"24","author":"Chen","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib17","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1681\/ASN.2007101075","article-title":"Uric acid and incident kidney disease in the community","volume":"19","author":"Weiner","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib18","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1681\/ASN.2008010080","article-title":"Elevated uric acid increases the risk for kidney disease","volume":"19","author":"Obermayr","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ccd.20598","article-title":"Hyperuricemia as a risk factor for contrast-induced nephropathy in patients with chronic kidney disease","volume":"67","author":"Toprak","year":"2006","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ndt\/gfh584","article-title":"Uric acid correlates with the severity of histopathological parameters in IgA nephropathy","volume":"20","author":"Myllym\u00e4ki","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib21","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1097\/01.tp.0000183895.88572.13","article-title":"Does uric acid have a pathogenetic role in graft dysfunction and hypertension in renal transplant recipients?","volume":"80","author":"Armstrong","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1053\/j.ajkd.2004.06.006","article-title":"Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort","volume":"44","author":"Iseki","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib23","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1291\/hypres.24.691","article-title":"Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects","volume":"24","author":"Iseki","year":"2001","journal-title":"Hypertens Res"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/ndt\/15.1.34","article-title":"Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy","volume":"15","author":"Syrj\u00e4nen","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1034\/j.1399-0012.1999.130502.x","article-title":"Influence of hyperglycemia and hyperuricemia on long-term transplant survival in kidney transplant recipients","volume":"13","author":"Gerhardt","year":"1999","journal-title":"Clin Transpl"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib26","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1053\/j.ajkd.2008.12.021","article-title":"Uric acid and long-term outcomes in CKD","volume":"53","author":"Madero","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib27","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3899\/jrheum.081199","article-title":"Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate","volume":"36","author":"See","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.exger.2008.01.006","article-title":"Uric acid as a risk factor for progression of non-diabetic chronic kidney disease?","volume":"43","author":"Sturm","year":"2008","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.ajkd.2007.05.013","article-title":"Relationship of uric acid with progression of kidney disease","volume":"50","author":"Chonchol","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0002-9610(88)80196-X","article-title":"Hyperuricemia after renal transplantation","volume":"156","author":"Gores","year":"1988","journal-title":"Am J Surg"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib31","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Asymptomatic hyperuricemia","volume":"82","author":"Campion","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib32","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/rheumatology\/ken070","article-title":"Hyperuricaemia\u2014Where nephrology meets rheumatology","volume":"47","author":"Avram","year":"2008","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib33","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/00007890-200111270-00021","article-title":"Hyperuricemia, gout, and renal function after liver transplantation","volume":"72","author":"Neal","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","article-title":"Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level","volume":"47","author":"Siu","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib35","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib36","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s11255-007-9253-3","article-title":"Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions","volume":"39","author":"Kanbay","year":"2007","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib37","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jama.300.8.924","article-title":"Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial","volume":"300","author":"Feig","year":"2008","journal-title":"Jama"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib38","first-page":"385","article-title":"The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: A pilot study","volume":"9","author":"Shelmadine","year":"2009","journal-title":"Anadolu Kardiyol Derg"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib39","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1681\/ASN.2010111185","article-title":"Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease","volume":"22","author":"Kao","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib40","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.3949\/ccjm.75.Suppl_5.S9","article-title":"Epidemiology of gout","volume":"75","author":"Weaver","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib41","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. part II: Management","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"6 Suppl 1","key":"10.1016\/j.semarthrit.2012.03.013_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3810\/pgm.2011.11.2511","article-title":"Recommendations for the diagnosis and management of gout and hyperuricemia","volume":"123","author":"Hamburger","year":"2011","journal-title":"Postgrad Med"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib43","first-page":"1487","article-title":"Drug dosing adjustments in patients with chronic kidney disease","volume":"75","author":"Munar","year":"2007","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib44","series-title":"Indocin (indomethacin) oral suspension [prescribing information]","year":"2008"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib45","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000045783","article-title":"Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts","volume":"86","author":"Perez-Ruiz","year":"2000","journal-title":"Nephron"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1046\/j.1365-2125.1997.00631.x","article-title":"Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects","volume":"44","author":"Henry","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib47","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1001\/jama.1980.03310100045031","article-title":"Indomethacin-induced hyperkalemia in three patients with gouty arthritis","volume":"244","author":"Findling","year":"1980","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib48","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/jama.1981.03320020046023","article-title":"Reversible acute renal insufficiency and hyperkalemia following indomethacin therapy","volume":"246","author":"Galler","year":"1981","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00000441-199608000-00008","article-title":"Case report: Diclofenac-induced rhabdomyolysis","volume":"312","author":"Delrio","year":"1996","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/03009748609092664","article-title":"Reversible non-oliguric impairment of renal function during azapropazone treatment","volume":"15","author":"Sipil\u00e4","year":"1986","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib51","first-page":"1566","article-title":"Treatment of acute gout in hospitalized patients","volume":"34","author":"Petersel","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib52","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1445-5994.2010.02165.x","article-title":"Acute gout management during hospitalisation: A need for a protocol","volume":"41","author":"Gnanenthiran","year":"2011","journal-title":"Int Med J"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib53","series-title":"Colcrys (cochicine USP) tablets [prescribing information]","year":"2010"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib54","first-page":"147","article-title":"Rhabdomyolysis induced by co-administration of fluvastatin and colchicine","volume":"74","author":"Sarullo","year":"2010","journal-title":"Monaldi Arch Chest Dis"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib55","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/RHU.0b013e318156d977","article-title":"Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine","volume":"13","author":"Justiniano","year":"2007","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib56","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1752-1947-1-64","article-title":"Acute pancreatitis related to therapeutic dosing with colchicine: A case report","volume":"1","author":"Ting","year":"2007","journal-title":"J Med Case Reports"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib57","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1432-2277.2002.tb00181.x","article-title":"Colchicine myoneuropathy in a renal transplant patient","volume":"15","author":"Dupont","year":"2002","journal-title":"Transpl Int"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib58","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00002826-200209000-00008","article-title":"Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin","volume":"25","author":"Hsu","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib59","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1592\/phco.24.17.1784.52334","article-title":"Colchicine myotoxicity: Case reports and literature review","volume":"24","author":"Wilbur","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib60","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0303-8467(97)00092-9","article-title":"Acute onset of colchicine myoneuropathy in cardiac transplant recipients: Case studies of three patients","volume":"99","author":"Rana","year":"1997","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib61","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S1053-2498(00)00175-3","article-title":"Post-cardiac transplantation gout: Incidence of therapeutic complications","volume":"19","author":"Wluka","year":"2000","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib62","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00124743-199606000-00011","article-title":"Colchicine neuromyopathy","volume":"2","author":"Uri","year":"1996","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib63","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/431592","article-title":"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: A retrospective study","volume":"41","author":"Hung","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib64","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1345\/aph.1E197","article-title":"Acute colchicine intoxication during clarithromycin administration","volume":"38","author":"Rollot","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib65","first-page":"U2808","article-title":"Colchicine prescribing and safety monitoring in patients with gout","volume":"120","author":"Ly","year":"2007","journal-title":"NZ Med J"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib66","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/ard.2008.092619","article-title":"Opportunities for improving medication use and monitoring in gout","volume":"68","author":"Singh","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005521.pub2","article-title":"Systemic corticosteroids for acute gout","volume":"2","author":"Janssens","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib68","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1 inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib69","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","article-title":"The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study","volume":"68","author":"Terkeltaub","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib70","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib71","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar3297","article-title":"Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: Results of a randomized, dose-ranging study","volume":"13","author":"Schlesinger","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib72","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/art.20277","article-title":"The safety of anakinra in high-risk patients with active rheumatoid arthritis: Six-month observations of patients with comorbid conditions","volume":"50","author":"Schiff","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib73","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1177\/0091270009351882","article-title":"Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD)","volume":"50","author":"Radin","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib74","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0009-9236(03)00094-8","article-title":"Pharmacokinetics of anakinra in subjects with different levels of renal function","volume":"74","author":"Yang","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib75","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11926-009-0019-z","article-title":"A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout","volume":"11","author":"Chao","year":"2009","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib76","series-title":"Allopurinol tablets USP [prescribing information]","year":"2006"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib77","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/RHU.0b013e318164dceb","article-title":"Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease","volume":"14","author":"Panomvana","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib78","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","article-title":"Allopurinol dosing in renal impairment: Walking the tightrope between adequate urate lowering and adverse events","volume":"20","author":"Dalbeth","year":"2007","journal-title":"Semin Dial"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib79","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib80","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib81","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/MAJ.0b013e31815acb10","article-title":"Optimizing therapy with allopurinol: Factors limiting hypouricemic efficacy","volume":"335","author":"Chung","year":"2008","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib82","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol","volume":"46","author":"Day","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib83","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/RHU.0b013e318204aab4","article-title":"Renal function in gout: Long-term treatment effects of febuxostat","volume":"17","author":"Whelton","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib84","first-page":"128","article-title":"Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients","volume":"4","author":"Momeni","year":"2010","journal-title":"Iran J Kidney Dis"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib85","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib86","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib87","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000105142","article-title":"The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease","volume":"27","author":"Talaat","year":"2007","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib88","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/qjmed\/95.9.597","article-title":"Early treatment with allopurinol in familial juvenile hyerpuricaemic nephropathy (FJHN) ameliorates the long-term progression of renal disease","volume":"95","author":"Fairbanks","year":"2002","journal-title":"QJM"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib89","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00124743-199904000-00003","article-title":"Treatment of chronic gout in patients with renal function impairment: An open, randomized, actively controlled study","volume":"5","author":"Perez-Ruiz","year":"1999","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib90","first-page":"384","article-title":"Allopurinol hypersensitivity syndrome: A preventable severe cutaneous adverse reaction?","volume":"49","author":"Lee","year":"2008","journal-title":"Singapore Med J"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib91","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/08860220701861045","article-title":"Allopurinol-induced recurrent DRESS syndrome: Pathophysiology and treatment","volume":"30","author":"Shalom","year":"2008","journal-title":"Ren Fail"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib92","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1093\/ndt\/gfr060","article-title":"HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency","volume":"26","author":"Jung","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib93","first-page":"656","article-title":"Allopurinol-induced DRESS syndrome","volume":"7","author":"Markel","year":"2005","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib94","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1345\/aph.1G105","article-title":"Hypersensitivity syndrome and pure red cell aplasia following allopurinol therapy in a patient with chronic kidney disease","volume":"39","author":"Chao","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib95","first-page":"156","article-title":"A review of inpatients with adverse drug reactions to allopurinol","volume":"41","author":"Khoo","year":"2000","journal-title":"Singapore Med J"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib96","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/archdermatol.2010.198","article-title":"Drug reaction with eosinophilia and systemic symptoms: A retrospective study of 60 cases","volume":"146","author":"Chen","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib97","first-page":"333","article-title":"Therapeutic alternatives in a patient with DRESS syndrome induced by allopurinol","volume":"19","author":"Calogiuri","year":"2009","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib98","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1607-551X(09)70192-5","article-title":"Allopurinol-induced severe hypersensitivity with acute renal failure","volume":"21","author":"Chen","year":"2005","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib99","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/bmj.312.7024.173","article-title":"Allopurinol, erythema multiforme, and renal insufficiency","volume":"312","author":"Kumar","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib100","first-page":"140","article-title":"Allopurinol hypersensitivity syndrome","volume":"27","author":"Lee","year":"1994","journal-title":"Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib101","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0002-9343(92)90236-5","article-title":"Desensitization to allopurinol in patients with gout and cutaneous reactions","volume":"93","author":"Fam","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib102","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0190-9622(79)70031-4","article-title":"The allopurinol hypersensitivity syndrome","volume":"1","author":"Lupton","year":"1979","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib103","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/bmj.2.6033.458","article-title":"Desensitisation in a patient with chronic renal disease and severe allergy to allopurinol","volume":"2","author":"Meyrier","year":"1976","journal-title":"Br Med J"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib104","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5414\/CNP71203","article-title":"Allopurinol-induced aplastic anemia in a patient with chronic kidney disease","volume":"71","author":"Kim","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib105","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/keh679","article-title":"Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: Results from the UK general practice research database (GPRD)","volume":"44","author":"Mikuls","year":"2005","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib106","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/art.22767","article-title":"Quality of care for gout in the US needs improvement","volume":"57","author":"Singh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib107","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib108","series-title":"Uloric (febuxostat) tablets for oral use [prescribing information]","year":"2011"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.013_bib111","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/RHU.0b013e31821d36f2","article-title":"A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: Pharmacokinetic and pharmacodynamic study","volume":"17","author":"Tatsuo","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib112","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1592\/phco.30.6.594","article-title":"Urate-lowering therapy for gout: Focus on febuxostat","volume":"30","author":"Love","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib113","doi-asserted-by":"crossref","first-page":"397646","DOI":"10.1155\/2011\/397646","article-title":"Tophaceous gout and renal insufficiency: A new solution for an old therapeutic dilemma","volume":"2011","author":"Tausche","year":"2011","journal-title":"Case Report Med"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib114","series-title":"Probenecid tablets [prescribing information]","year":"2003"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib115","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3899\/jrheum.101160","article-title":"Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout","volume":"38","author":"Stocker","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib116","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2147\/TCRM.S6043","article-title":"New advances in the treatment of gout: Review of pegloticase","volume":"6","author":"Reinders","year":"2010","journal-title":"Ther Clin. Risk Manag"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib117","series-title":"Krystexxa","year":"2010"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib118","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib119","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1002\/art.23993","article-title":"Resolution of gouty tophi after twelve weeks of pegloticase treatment","volume":"58","author":"Baraf","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.7182\/prtr.14.2.dr3j76l1603k0145","article-title":"Treating gout in kidney transplant recipients","volume":"14","author":"Baroletti","year":"2004","journal-title":"Prog Transplant"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib121","series-title":"Sandimmune (cyclosporine) [prescribing information]","year":"2011"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib122","series-title":"Prograf (tacrolimus) [prescribing information]","year":"2012"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib123","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3949\/ccjm.77a.09080","article-title":"Managing gout: How is it different in patients with chronic kidney disease?","volume":"77","author":"El-Zawawy","year":"2010","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib124","series-title":"Medrol (methylprednisolone, USP) tablets [prescribing information]","year":"2006"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib125","series-title":"Orapred ODT (prednisolone sodium phosphate) [prescribing information]","year":"2010"},{"key":"10.1016\/j.semarthrit.2012.03.013_bib126","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMcp1001124","article-title":"Clinical practice","volume":"364","author":"Neogi","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901721200087X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901721200087X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T01:11:08Z","timestamp":1561684268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004901721200087X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":124,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S004901721200087X"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2012.03.013","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}